Fig. 1 · Structure

Documents & Downloads

Biperiden HCl

Cat. No. A10147 CAS 1235-82-1

muscarinic receptor antagonist

Biperiden hydrochloride is a muscarinic receptor antagonist that displays some selectivity for the M1 subtype

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biperiden HCl Research Summary

This section summarizes 2 in vivo studies of Biperiden HCl from 1 published reference.

Biperiden HCl In Vivo Studies

In male Wistar rats given biperiden hydrochloride (3 mg/kg, subcutaneous), final-probe target-quadrant time was lower than in the reported control group, while reversal learning showed no main treatment effect. The paper’s solvent recipes leave final DMSO matching unclear. [1]

Delayed matching to position showed no main treatment effect or treatment-by-interval interaction, despite a fourth-trial latency difference. Visible-platform performance was similar between groups. These mixed results limit interpretation as a selective working-memory impairment model. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reversal learning and associated retention probes

Animal study · Male Wistar rats; biperiden n = 10, control n = 12 at design entry. [1]

Reversal learning showed no main treatment effect. In the final probe, the treated group spent less time in the target quadrant than controls. Solvent matching is unclear from the reported formulations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Escape latency: main effect of biperiden administrationReported group comparison t(19.9) = −0.49; p = 0.63; b = −1.37; 95% CI [−6.79, 4.05][1]
Final reversal-day target-quadrant timeReported group comparison M_biperiden = 22.05 s; M_control = 30.87 s; t(19) = −2.97; p = 0.008; d = −1.27; 95% CI [−2.19, −0.33][1]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Before the daily testing session
Vehicle
DMSO/saline. Drug: 100 μL DMSO per 1 mg BIP, diluted to 3 mg/mL. Control: 300 μL DMSO per 1 mL saline, as written.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Biperiden
3 mg/kg
Reported DMSO/saline controlFinal probe target-quadrant mean 22.05 s; reversal learning main treatment effect nonsignificant.[1]
Vehicle control
Vehicle only
Comparator for biperiden armFinal probe target-quadrant mean 30.87 s.[1]
Biperiden
Model: Male Wistar rats, n = 10
Treatment course: Days 4–5 of a five-day task
Reported limits: Enantiomeric composition and unambiguous matching of final solvent proportions are not established.
Vehicle control
Model: Male Wistar rats, n = 12
Treatment course: Five-day task; drug treatment comparison on days 4–5
Reported limits: Enantiomeric composition and unambiguous matching of final solvent proportions are not established.
Methods and source locations

Compound reported in the paper: Biperiden hydrochloride; Compound label in the paper: BIP

Published hydrochloride experiment; no Adooq lot validation or equivalence of stereochemical composition is established.

PDF p.3, Experimental procedures: Animals and Drugs; Reversal design pp.3–4; statistical analysis p.5; Results p.6; Figs.4a and 5a, pp.7–8

Escape latency: main effect of biperiden administration: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF p.6, Results: Reversal; Fig.4a on p.7

Final reversal-day target-quadrant time: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF p.6, Results: Probe trials—reversal; Fig.5a on p.8

Biperiden · PDF p.3, Experimental procedures: Animals and Drugs; Reversal design on pp.3–4; Results p.6; Figs.4a,5a

Vehicle control · PDF p.3, Experimental procedures: Animals and Drugs; Reversal design on pp.3–4; Results p.6; Fig.5a

Delayed matching to position with visible-platform control

Animal study · Male Wistar rats; DMP design entry n = 21 per group. Visible-platform test followed DMP in this cohort. [1]

There was no main effect on DMP escape latency or interaction with inter-trial interval. Treated rats had higher latency in trial four; visible-platform performance did not differ. These results do not establish a selective working-memory deficit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DMP escape latency: main treatment effectReported group comparison t(38.6) = 1.07; p = 0.29; b = 1.94; 95% CI [−1.62, 5.49][1]
DMP escape latency: inter-trial interval × groupReported group comparison t(953.8) = −0.16; p = 0.87; b = −0.36; 95% CI [−4.79, 4.07][1]
DMP escape latency in the fourth trial: treated versus controlReported group comparison t(40.2) = 3.87; p < 0.001; b = 8.35; 95% CI [4.12, 12.58][1]
Visible-platform escape latency: group differenceReported group comparison t(30.0) = −0.04; p = 0.97; b = −0.13; 95% CI [−6.21, 5.95][1]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Before the daily testing session
Treatment course
Eight DMP days; visible-platform session followed
Vehicle
DMSO/saline. Drug: 100 μL DMSO per 1 mg BIP, diluted to 3 mg/mL. Control: 300 μL DMSO per 1 mL saline, as written.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Biperiden
3 mg/kg
Reported DMSO/saline controlNo main DMP effect; higher fourth-trial latency; no visible-platform group difference.[1]
Vehicle control
Vehicle only
Comparator for biperiden armReference group for DMP and visible-platform comparisons.[1]
Biperiden
Model: Male Wistar rats; DMP design n = 21
Reported limits: Enantiomeric composition and unambiguous matching of final solvent proportions are not established.
Vehicle control
Model: Male Wistar rats; DMP design n = 21
Reported limits: Enantiomeric composition and unambiguous matching of final solvent proportions are not established.
Methods and source locations

Compound reported in the paper: Biperiden hydrochloride; Compound label in the paper: BIP

Published hydrochloride experiment; no Adooq lot validation or equivalence of stereochemical composition is established.

PDF p.3, Experimental procedures: Animals and Drugs; DMP design p.4; statistical analysis p.5; Results pp.6–8; Figs.4b and 5b, pp.7–8

DMP escape latency: main treatment effect: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF p.6, Results: Delayed matching to position; Fig.4b, p.7

DMP escape latency: inter-trial interval × group: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF pp.6–7, Results: Delayed matching to position

DMP escape latency in the fourth trial: treated versus control: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF p.8, Results: Delayed matching to position; Fig.4b, p.7

Visible-platform escape latency: group difference: Mixed-effect regression; numbers transcribed from Results, not estimated from plots. — PDF p.8, Results: Visible platform; Fig.5b

Biperiden · PDF p.3, Experimental procedures: Animals and Drugs; DMP design p.4; analysis p.5; Results pp.6–8; Figs.4b,5b

Vehicle control · PDF p.3, Experimental procedures: Animals and Drugs; DMP design p.4; analysis p.5; Results pp.6–8; Figs.4b,5b

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 1235-82-1
Applications muscarinic receptor antagonist
Formula C21H29NO.HCl
Molecular Weight 347.9
Synonyms Akineton
SMILES
C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Biperiden HCl Research References

  1. [1] Anna Popelíková, Štěpán Bahník, Veronika Lobellová, et al. Mnemonic and behavioral effects of biperiden, an M1-selective antagonist, in the rat. Psychopharmacology (2018). PMID: 29680966 DOI: 10.1007/s00213-018-4899-3 Source material

Added to your cart

View Cart Checkout
Loading...